Co-development initiatives to advance next-generation workflows, accelerate adoption, and expand the role of AI within model-informed drug development Simulations Plus, Inc. (Nasdaq: SLP) ...
LANCASTER, Calif.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced ...
Simulations Plus is benefiting from the growing use of computational tools in drug discovery, which would be boosted by the FDA Modernization Act 2.0. The biosimulation market is highly fragmented and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results